Autopsy report · NCT03829501

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

“Early discontinuation based on strategic sponsor decision not driven by any safety concerns.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 5 years 8 months before it stopped.
• 222 participants enrolled.
• Results were posted on the registry 6 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Kymab Limited

Sponsor type

Industry

Conditions

Squamous Cell Carcinoma of Head and Neck; Non-small Cell Lung Cancer; Hepatocellular Carcinoma; Esophageal Cancer; Gastric Cancer; Melanoma

Interventions

Alomfilimab; Atezolizumab

Participants

222

Sites

22

Countries

Hungary, Italy, Poland, Taiwan, United Kingdom, United States

Trials that died the same way

• Goal Attainment and Physical Activity in People With Hemophilia A
  “Early discontinuation based on sponsor decision not driven by any safety concerns.” (96% match in meaning)
• Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma
  “Sponsor decided to discontinue the study due to strategic considerations and not due to any safety-related concerns.” (79% match in meaning)
• REGENETEN™ Bioinductive Implant System in Full-thickness Tears
  “Sponsor decision not related to safety.” (71% match in meaning)
• JSP191 Antibody Targeting Conditioning in SCID Patients
  “Sponsor Decision - terminated due to changes in company priorities and not related to safety concerns.” (71% match in meaning)
• Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
  “Sponsor decision; the decision is not related to any safety concern.” (69% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.